To further delineate the molecular mechanisms underlying the protective effects of phosphatidylcholine, and to delineate if PPARγ2 might be critical herein, J774A.1 cells and human primary monocytes, respectively, were either preincubated with phosphatidylcholine, GW9662, an antagonist of PPARγ shown to attenuate the induction of PPARγ2 in mice with diet-induced MASLD,10 or the PPARγ activator pioglitazone. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.